Skip to main content
RELMADA THERAPEUTICS, INC. logo

RELMADA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · RLMD ISIN · US75954H1005 LEI · 549300217EASRZ9JSF81 US Professional, scientific and technical activities
Open in API
Filings indexed 582 across all filing types
Latest filing 2019-02-28 Declaration of Voting R…
Country US United States of America
Listing US RLMD

About RELMADA THERAPEUTICS, INC.

https://www.relmada.com/

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company developing novel therapies. The company's lead program is NDV-01, a sustained-release, intravesical formulation of gemcitabine and docetaxel for the treatment of non-muscle invasive bladder cancer. The formulation is designed for gradual drug release over 10 days to enhance local exposure and minimize systemic toxicity. Relmada's pipeline also includes Sepranolone, which is being developed for compulsive disorders. Following positive proof-of-concept data in Tourette’s syndrome, the company is planning a Phase 2 study of Sepranolone in Prader-Willi Syndrome, a rare genetic disorder.

Recent filings

Filing Released Lang Actions
CURRENT REPORT
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated February 27, 2019, by Relmada Therapeutics, Inc. The content focuses on the submission of matters to a vote of security holders at the 2018 Annual Meeting of Stockholders. It details voting results for director elections, ratification of the independent auditor, and amendments to stock plans and articles of incorporation. The document is not a full annual report or financial statement but specifically reports the official results of shareholder votes at the annual meeting. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 4444 characters, which is consistent with a detailed voting results announcement rather than a brief notice or a full report.
2019-02-28 English
Regulatory Filings 2019
Regulatory Filings Classification · 95% confidence The document is a letter from Relmada Therapeutics, Inc. to the SEC requesting acceleration of effectiveness of a Registration Statement on Form S-1. It references Rule 461 under the Securities Act of 1933 and discusses procedural acknowledgments related to the filing's effectiveness. The document is short (1904 characters) and is clearly an announcement or request related to a regulatory filing rather than a financial report or detailed filing itself. It does not contain financial data, audit information, or detailed report content. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2019-02-28 English
AMENDMENT NO. 1 TO REGISTRATION STATEMENT
Capital/Financing Update Classification · 100% confidence The document is a Form S-1/A, which is an amendment to a registration statement filed with the SEC under the Securities Act of 1933. It includes detailed information about the company's securities offering, including the number of shares, pricing, selling stockholders, risk factors, business overview, and financial information. This type of filing is related to capital raising activities and securities registration rather than financial performance reporting or management discussion. It is not an annual report, earnings release, or any other financial report type. The document is a registration statement amendment for a securities offering, which fits the category of Capital/Financing Update (CAP).
2019-02-26 English
QUARTERLY REPORT
Interim / Quarterly Report Q2 2019
2019-02-13 English
CURRENT REPORT
Regulatory Filings Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated February 6, 2019. It reports the entry into a material definitive agreement, specifically a settlement agreement and consulting agreement involving the company and an individual. The content focuses on legal and contractual updates rather than financial results or detailed financial statements. The document is not an annual or quarterly report, earnings release, or audit report. It is a regulatory filing that announces a significant corporate event (settlement and consulting agreement) but does not fit into more specific categories like M&A or management changes. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length is just over 5,000 characters, but the content is clearly a current report filing rather than a report publication announcement or certification.
2019-02-11 English
Regulatory Filings 2019
Regulatory Filings
2019-02-08 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.